Key facts
- It has raised $185.0M across 1 recorded rounds; the latest was PIPE ($185.0M) in Mar 2024.
- 2 institutional filers report fund marks on Avalo Therapeutics across 4 filings.
- Avalo Therapeutics has filed 1 Form D with the SEC, most recently Apr 2024 ($130.6M sold to 25 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Avalo Therapeutics
Create free account
No card required
Funding rounds
1 roundsMar 2024PIPE$185.0M▮
About Avalo Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Avalo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Avalo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 4 fair-value marks on Avalo Therapeutics between Oct 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.